Observational studyMedicine2026
Echocardiographic factors suggestive of pulmonary hypertension in patients with mediastinal tumors: A single-center observational study.
Observational study in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pulmonary hypertension (PH) may occur in diverse clinical contexts. Group 5 PH includes conditions with unclear or multifactorial mechanisms, including tumor-associated PH. Evidence regarding the frequency and clinical significance of elevated right ventricular systolic pressure (RVSP) in patients with mediastinal tumors (MT) is limited. This study aimed to identify clinical and echocardiographic factors associated with elevated RVSP suggestive of PH in patients with MT. This retrospective observational study included patients with MT who underwent transthoracic echocardiography (TTE) at a single tertiary center from January 2010 to December 2019. Clinical variables and echocardiographic parameters were compared between patients with and without elevated RVSP. Echocardiographic signs suggestive of PH were defined as an estimated RVSP ≥ 35 mm Hg; PH was not confirmed by right-heart catheterization. Fifty-five patients (mean age, 62 ± 13 years; 31 women [56%]) were analyzed. Echocardiographic signs suggestive of PH were observed in 21 patients (38%). Twenty-two patients were asymptomatic, and no symptoms were clearly attributable to elevated RVSP. Forty-seven patients (86%) underwent surgery, and 24 (44%) had malignant tumors; elevated RVSP was not associated with malignancy. Patients with elevated RVSP were older than those without elevated RVSP (67 ± 10 vs 59 ± 14 years, P = .017). Smaller left ventricular (LV) end-systolic (29.4 ± 3.6 vs 31.6 ± 3.6 mm, P = .040) and end-diastolic dimensions (4.2 ± 0.3 vs 4.5 ± 0.3 cm, P = .004), and higher LV ejection fraction (LVEF; 69 ± 6% vs 65 ± 5%, P = .019), were associated with elevated RVSP. In exploratory multivariable analysis, older age, smaller LV dimensions, and higher LVEF remained independently associated with elevated RVSP. Elevated RVSP was not significantly associated with clinical symptoms or malignancy. Echocardiographic signs suggestive of PH were relatively common in patients with MT and were associated with older age, smaller LV dimensions, and relatively hyperdynamic LV function. These findings represent echocardiographic associations rather than invasively confirmed PH and require validation in larger prospective studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.